Phase 2 Readout~quarter
Phase 2 Readout: nexicart-2
- Company
- JOHNSON & JOHNSON (JNJ)
- Drug
- nexicart-2
- Indication
- Relapsed/Refractory AL Amyloidosis
Other upcoming events for JNJ
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy i
Phase 3 ReadoutPhase 3 Topline: Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
Phase 3 ReadoutPhase 3 Topline: Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.